SCHEMBL419285

SCHEMBL419285

CCOC(=O)c1cc(Br)c(-c2cccc(C#N)c2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.46
FNTB P49356 1/20 0.46
CNR2 P34972 1/20 0.46
TLR8 Q9NR97 1/20 0.45
TLR7 Q9NYK1 1/20 0.45
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
ALOX5 P09917 2/20 0.42
MEN1 O00255 1/20 0.41
PRNP P04156 1/20 0.41
KMT2A Q03164 1/20 0.41
HRH2 P25021 1/20 0.41
HRH1 P35367 1/20 0.41
POLB P06746 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
SETD7 Q8WTS6 1/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421079 0.82 ALOX5 (0.55) ALOX5MEN1PRNPKMT2AMAPT
SCHEMBL2510358 0.82 CNR2 (0.44) FNTAFNTBCNR2TLR8TLR7
SCHEMBL420790 0.81 TLR8 (0.43) FNTAFNTBCNR2TLR8TLR7
SCHEMBL419840 0.78 FNTA (0.42) FNTAFNTBCNR2TLR8TLR7
SCHEMBL417915 0.75 MAPT (0.45) MEN1PRNPKMT2AMAPTKDM4E
SCHEMBL4445717 0.75 TLR8 (0.54) FNTAFNTBCNR2TLR8TLR7
SCHEMBL420126 0.74 ALOX5 (0.45) FNTAFNTBTLR8TLR7ALOX5
SCHEMBL18987085 0.74 CA1 (0.54) FNTAFNTBCNR2TLR8TLR7
SCHEMBL29470216 0.74 CA1 (0.54) FNTAFNTBCNR2TLR8TLR7
SCHEMBL418485 0.73 MAOB (0.44) ALOX5MEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT FNTA 725/4885FNTB 1001/4885CNR2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.